VG Life Sciences Inc (VGLS) 0.0432 $VGLS
Lung Adenocarcinoma Pipeline Review, H1 2015 - 19 Companies & 27 Drug Profiles
M2 - Thu Jul 09, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vrdth/lung) has announced the addition of the "Lung Adenocarcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Axelar AB - Bayer AG - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - DiNonA Inc. - Eisai Co., Ltd. - Genentech, Inc. - Genmab A/S - Immunomedics, Inc. - Incyte Corporation - Medisyn Technologies, Inc. - Pfizer Inc. - Sanofi - VG Life Sciences, Inc. - Vichem Chemie Research Ltd. Drug Profiles - 4-B4 - afatinib - AV-203 - AXL-1717 - AZD-6738 - BAY-1163877 - Cell Therapy to Activate CD40L and GM-CSF for Metastatic Lung Adenocarcinoma - dacomitinib - DBPR-112 - dimesna - hydroxychloroquine sorafenib tosylate - Interferon Lambda-1 Linked Fab Dimer - lenvatinib - MAG-Tn3 - MT-477 - ruxolitinib phosphate - SAR-408701 - Small Molecule for Cancer - Small Molecule to Inhibit EGFR for Oncology - Small Molecules to Activate PKM2 for Lung Adenocarcinoma - Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma - SNX-5422 - solitomab - Stem Cell Therapy for Oncology - TdCyd - TF-011 Monomethyl Auristatin E - Vaccine for Lung Adenocarcinoma For more information visit http://www.researchandmarkets.com/research/3vrdth/lung
IMMU: 2.22 (+0.01), PFE: 32.97 (+0.35), INCY: 131.01 (+6.51), AZN: 33.30 (+0.02), AVEO: 1.36 (unch), AMGN: 153.21 (+0.07)
VGLS Notes Key Patents, License and Other Major Achievements in the First Half of 2015
PR Newswire - Tue Jun 16, 3:28PM CDT
Dear Shareholders,
Global Pre-Eclampsia Therapeutics Pipeline Review, H1 2015 - 7 Companies & 8 Drug Profiles
M2 - Fri Jun 05, 5:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/78h8rl/preeclampsia) has announced the addition of the "Pre-Eclampsia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pre-Eclampsia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pre-Eclampsia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A1M Pharma AB - Alnylam Pharmaceuticals, Inc. - Glenveigh Medical, LLC - Pluristem Therapeutics Inc. - rEVO Biologics - VG Life Sciences, Inc. Drug Profiles - ALN-AGT - Alpha-1-Microglobulin - antithrombin alfa (recombinant) - digoxin immune fab - Monoclonal Antibodies for Cardiovascular Diseases - Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Stem Cell Therapy for Pre-Eclampsia - VG-1177 For more information visit http://www.researchandmarkets.com/research/78...eeclampsia
PSTI: 2.07 (-0.03), RBIO: ()
Global Lyme Disease Pipeline Report 2015 - 4 Companies & 7 Drug Profiles
M2 - Wed May 20, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fttftx/lyme_disease) has announced the addition of the "Lyme Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lyme Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lyme Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxter International Inc. - LondonPharma Ltd - Valneva SE - VG Life Sciences, Inc. Drug Profiles - azithromycin gel - lyme borreliosis vaccine - lyme disease vaccine - lyme disease vaccine 2 - Small Molecule for Lyme Disease - VGV-L - VLA-15 For more information visit http://www.researchandmarkets.com/research/ft...me_disease
BAX: 36.02 (-0.05)
Global Traumatic Brain Injury Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f9f48/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - ALSP, Inc. - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Io Therapeutics, Inc. - Ischemix - Karyopharm Therapeutics, Inc. - Kyorin Pharmaceutical Co., Ltd. - Levolta Pharmaceuticals, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - PharmatrophiX, Inc. - Phylogica Limited - Prevacus, Inc. - PsychoGenics, Inc. - QR Pharma, Inc. - RAPID Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - SynZyme Technologies, LLC - Tetra Discovery Partners LLC - vasopharm GmbH - VG Life Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/9f...atic_brain
NBS: 2.25 (-0.09), LPTN: 0.23 (unch), CNCE: 19.27 (+0.68), ATHX: 1.20 (-0.02), KPTI: 14.95 (+0.41), CUR: 1.53 (+0.02)
VG Life Sciences Granted Key Composition of Matter Patent
GlobeNewswire - Mon Mar 02, 9:07AM CST
VG Life Sciences, Inc., (OTCQB:VGLS), a biotechnology company developing therapies for autoimmune and infectious diseases, announced that the U.S. Patent and Trademark Office (USPTO) has issued an important new composition of matter patent covering methods for modulating immune system function through the targeting of CLIP.
VG Life Sciences Announces Issuance of Patent Covering Treatment of Inflammatory Bowel Disease with Clip-Inducing Agent
GlobeNewswire - Thu Jan 29, 9:04AM CST
VG Life Sciences, (VGLS), a biotechnology company developing therapies for autoimmune and infectious diseases, today announced the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8906846, covering a method of treating inflammatory bowel disease (IBD) through the administration of a CLIP-inducing agent.
VG Life Sciences Announces Issuance Of Patent Covering Treatment Of Inflammatory Bowel Disease With CLIP-Inducing Agent
PR Newswire - Thu Jan 29, 8:28AM CST
VG Life Sciences, (VGLS), a biotechnology company developing therapies for autoimmune and infectious diseases, today announced the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8906846, covering a method of treating inflammatory bowel disease (IBD) through the administration of a CLIP-inducing agent.
VGLS Q4 2014 Shareholder Update Letter
GlobeNewswire - Wed Jan 14, 9:13AM CST
VG Life Sciences Inc. releases a Q4 2014 Shareholder Update Letter:
Lung Adenocarcinoma - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/c2qszp/lung) has announced the addition of the "Lung Adenocarcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lung Adenocarcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lung Adenocarcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - Astex Pharmaceuticals - AstraZeneca - Axelar - Bayer - BioNumerik Pharmaceuticals - Boehringer Ingelheim - Genentech - Genmab - Hanmi Pharmaceuticals - Immunomedics - Medisyn Technologies - Pfizer - Sanofi - VG Life Sciences, Inc. - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/c2qszp/lung
IMMU: 2.22 (+0.01), AMGN: 153.21 (+0.07)
New Data Implicate Components of Adaptive Immunity in Traumatic Brain Injury
GlobeNewswire - Mon Oct 20, 8:39AM CDT
VG Life Sciences Inc., (OTCQB:VGLS) a biotechnology company, announces today that one of its scientific advisors, Dr. Richard Tobin, PhD, published data demonstrating that when there is traumatic brain injury (TBI), the body inflicts additional neural damage via the immune system. The data generated by Dr. Tobin shows immune therapy using VG Life Sciences' patented drug VG1177 can improve the condition.
VG Life Sciences Inc. Announces Upgrading to OTCQB Marketplace
GlobeNewswire - Thu Oct 16, 5:03PM CDT
VG Life Sciences Inc. (OTCQB: VGLS) is a biotechnology company focused on developing treatments for patients suffering from autoimmune and infectious diseases.
VG LIFE SCIENCES, INC. ANNOUNCES SEC FORM 10 REVIEW COMPLETE
GlobeNewswire - Tue Oct 14, 3:41PM CDT
VG Life Sciences Inc. (VGLS) is a publically traded biotechnology company focused on developing treatments for patients suffering from autoimmune and infectious diseases. VG Life Sciences is pleased to announce the Securities & Exchange Commission has completed their review of the company's Form 10 filing. The Form 10 was submitted on June 20, 2014 and provided comprehensive information about the capital structure, financial condition, history and governance of the company. A copy of the SEC letter is here.
Metastatic Ovarian Cancer Therapeutics Pipeline Review 2014 - 8 Companies and 11 Drug Profiles
M2 - Tue Sep 23, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rfq7sb/metastatic) has announced the addition of the "Metastatic Ovarian Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Millennium Pharmaceuticals, Inc. - Eisai Co., Ltd. - Northwest Biotherapeutics, Inc. - VG Life Sciences, Inc. - Immune Design Corp. - Aura Biosciences, Inc. Drug Profiles - bevacizumab - orteronel - antigen-presenting dendritic cells (living, autologous) - E-7449 - DCVax-Direct - Stem Cell Therapy for Oncology - hydroxychloroquine sorafenib tosylate - LV-305 - G-305 - Drugs for Metastatic Ovarian Cancer - SM-276001 For more information visit http://www.researchandmarkets.com/research/rfq7sb/metastatic
IMDZ: 16.25 (+0.24), NWBO: 7.44 (-0.23)
VG Life Sciences' Advisor Gives Preeclampsia Presentation at American Heart Association Conference
GlobeNewswire - Fri Sep 12, 7:42AM CDT
VG Life Sciences, (OTC Pink:VGLS) a biotechnology company, announces that one of its scientific advisors, Dr. Brett Mitchell, PhD, will give an oral presentation today on his preeclampsia research at the American Heart Association Council for High Blood Pressure Research Conference in San Francisco, California. Using pregnant mice who cannot genetically display MHC Class II invariant chain (CD74), the research showed the mice do not develop preeclampsia.
Lung Adenocarcinoma Pipeline Review, H1 2015 - 19 Companies & 27 Drug Profiles
M2 - Thu Jul 09, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vrdth/lung) has announced the addition of the "Lung Adenocarcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Axelar AB - Bayer AG - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - DiNonA Inc. - Eisai Co., Ltd. - Genentech, Inc. - Genmab A/S - Immunomedics, Inc. - Incyte Corporation - Medisyn Technologies, Inc. - Pfizer Inc. - Sanofi - VG Life Sciences, Inc. - Vichem Chemie Research Ltd. Drug Profiles - 4-B4 - afatinib - AV-203 - AXL-1717 - AZD-6738 - BAY-1163877 - Cell Therapy to Activate CD40L and GM-CSF for Metastatic Lung Adenocarcinoma - dacomitinib - DBPR-112 - dimesna - hydroxychloroquine sorafenib tosylate - Interferon Lambda-1 Linked Fab Dimer - lenvatinib - MAG-Tn3 - MT-477 - ruxolitinib phosphate - SAR-408701 - Small Molecule for Cancer - Small Molecule to Inhibit EGFR for Oncology - Small Molecules to Activate PKM2 for Lung Adenocarcinoma - Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma - SNX-5422 - solitomab - Stem Cell Therapy for Oncology - TdCyd - TF-011 Monomethyl Auristatin E - Vaccine for Lung Adenocarcinoma For more information visit http://www.researchandmarkets.com/research/3vrdth/lung
IMMU: 2.22 (+0.01), PFE: 32.97 (+0.35), INCY: 131.01 (+6.51), AZN: 33.30 (+0.02), AVEO: 1.36 (unch), AMGN: 153.21 (+0.07)
VGLS Notes Key Patents, License and Other Major Achievements in the First Half of 2015
PR Newswire - Tue Jun 16, 3:28PM CDT
Dear Shareholders,
Global Pre-Eclampsia Therapeutics Pipeline Review, H1 2015 - 7 Companies & 8 Drug Profiles
M2 - Fri Jun 05, 5:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/78h8rl/preeclampsia) has announced the addition of the "Pre-Eclampsia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pre-Eclampsia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pre-Eclampsia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A1M Pharma AB - Alnylam Pharmaceuticals, Inc. - Glenveigh Medical, LLC - Pluristem Therapeutics Inc. - rEVO Biologics - VG Life Sciences, Inc. Drug Profiles - ALN-AGT - Alpha-1-Microglobulin - antithrombin alfa (recombinant) - digoxin immune fab - Monoclonal Antibodies for Cardiovascular Diseases - Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Stem Cell Therapy for Pre-Eclampsia - VG-1177 For more information visit http://www.researchandmarkets.com/research/78...eeclampsia
PSTI: 2.07 (-0.03), RBIO: ()
Global Lyme Disease Pipeline Report 2015 - 4 Companies & 7 Drug Profiles
M2 - Wed May 20, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fttftx/lyme_disease) has announced the addition of the "Lyme Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lyme Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lyme Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxter International Inc. - LondonPharma Ltd - Valneva SE - VG Life Sciences, Inc. Drug Profiles - azithromycin gel - lyme borreliosis vaccine - lyme disease vaccine - lyme disease vaccine 2 - Small Molecule for Lyme Disease - VGV-L - VLA-15 For more information visit http://www.researchandmarkets.com/research/ft...me_disease
BAX: 36.02 (-0.05)
Global Traumatic Brain Injury Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f9f48/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - ALSP, Inc. - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Io Therapeutics, Inc. - Ischemix - Karyopharm Therapeutics, Inc. - Kyorin Pharmaceutical Co., Ltd. - Levolta Pharmaceuticals, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - PharmatrophiX, Inc. - Phylogica Limited - Prevacus, Inc. - PsychoGenics, Inc. - QR Pharma, Inc. - RAPID Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - SynZyme Technologies, LLC - Tetra Discovery Partners LLC - vasopharm GmbH - VG Life Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/9f...atic_brain
NBS: 2.25 (-0.09), LPTN: 0.23 (unch), CNCE: 19.27 (+0.68), ATHX: 1.20 (-0.02), KPTI: 14.95 (+0.41), CUR: 1.53 (+0.02)
VG Life Sciences Granted Key Composition of Matter Patent
GlobeNewswire - Mon Mar 02, 9:07AM CST
VG Life Sciences, Inc., (OTCQB:VGLS), a biotechnology company developing therapies for autoimmune and infectious diseases, announced that the U.S. Patent and Trademark Office (USPTO) has issued an important new composition of matter patent covering methods for modulating immune system function through the targeting of CLIP.
VG Life Sciences Announces Issuance of Patent Covering Treatment of Inflammatory Bowel Disease with Clip-Inducing Agent
GlobeNewswire - Thu Jan 29, 9:04AM CST
VG Life Sciences, (VGLS), a biotechnology company developing therapies for autoimmune and infectious diseases, today announced the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8906846, covering a method of treating inflammatory bowel disease (IBD) through the administration of a CLIP-inducing agent.
VG Life Sciences Announces Issuance Of Patent Covering Treatment Of Inflammatory Bowel Disease With CLIP-Inducing Agent
PR Newswire - Thu Jan 29, 8:28AM CST
VG Life Sciences, (VGLS), a biotechnology company developing therapies for autoimmune and infectious diseases, today announced the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8906846, covering a method of treating inflammatory bowel disease (IBD) through the administration of a CLIP-inducing agent.
VGLS Q4 2014 Shareholder Update Letter
GlobeNewswire - Wed Jan 14, 9:13AM CST
VG Life Sciences Inc. releases a Q4 2014 Shareholder Update Letter:
Lung Adenocarcinoma - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/c2qszp/lung) has announced the addition of the "Lung Adenocarcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lung Adenocarcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lung Adenocarcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - Astex Pharmaceuticals - AstraZeneca - Axelar - Bayer - BioNumerik Pharmaceuticals - Boehringer Ingelheim - Genentech - Genmab - Hanmi Pharmaceuticals - Immunomedics - Medisyn Technologies - Pfizer - Sanofi - VG Life Sciences, Inc. - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/c2qszp/lung
IMMU: 2.22 (+0.01), AMGN: 153.21 (+0.07)
New Data Implicate Components of Adaptive Immunity in Traumatic Brain Injury
GlobeNewswire - Mon Oct 20, 8:39AM CDT
VG Life Sciences Inc., (OTCQB:VGLS) a biotechnology company, announces today that one of its scientific advisors, Dr. Richard Tobin, PhD, published data demonstrating that when there is traumatic brain injury (TBI), the body inflicts additional neural damage via the immune system. The data generated by Dr. Tobin shows immune therapy using VG Life Sciences' patented drug VG1177 can improve the condition.
VG Life Sciences Inc. Announces Upgrading to OTCQB Marketplace
GlobeNewswire - Thu Oct 16, 5:03PM CDT
VG Life Sciences Inc. (OTCQB: VGLS) is a biotechnology company focused on developing treatments for patients suffering from autoimmune and infectious diseases.
VG LIFE SCIENCES, INC. ANNOUNCES SEC FORM 10 REVIEW COMPLETE
GlobeNewswire - Tue Oct 14, 3:41PM CDT
VG Life Sciences Inc. (VGLS) is a publically traded biotechnology company focused on developing treatments for patients suffering from autoimmune and infectious diseases. VG Life Sciences is pleased to announce the Securities & Exchange Commission has completed their review of the company's Form 10 filing. The Form 10 was submitted on June 20, 2014 and provided comprehensive information about the capital structure, financial condition, history and governance of the company. A copy of the SEC letter is here.
Metastatic Ovarian Cancer Therapeutics Pipeline Review 2014 - 8 Companies and 11 Drug Profiles
M2 - Tue Sep 23, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rfq7sb/metastatic) has announced the addition of the "Metastatic Ovarian Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Millennium Pharmaceuticals, Inc. - Eisai Co., Ltd. - Northwest Biotherapeutics, Inc. - VG Life Sciences, Inc. - Immune Design Corp. - Aura Biosciences, Inc. Drug Profiles - bevacizumab - orteronel - antigen-presenting dendritic cells (living, autologous) - E-7449 - DCVax-Direct - Stem Cell Therapy for Oncology - hydroxychloroquine sorafenib tosylate - LV-305 - G-305 - Drugs for Metastatic Ovarian Cancer - SM-276001 For more information visit http://www.researchandmarkets.com/research/rfq7sb/metastatic
IMDZ: 16.25 (+0.24), NWBO: 7.44 (-0.23)
VG Life Sciences' Advisor Gives Preeclampsia Presentation at American Heart Association Conference
GlobeNewswire - Fri Sep 12, 7:42AM CDT
VG Life Sciences, (OTC Pink:VGLS) a biotechnology company, announces that one of its scientific advisors, Dr. Brett Mitchell, PhD, will give an oral presentation today on his preeclampsia research at the American Heart Association Council for High Blood Pressure Research Conference in San Francisco, California. Using pregnant mice who cannot genetically display MHC Class II invariant chain (CD74), the research showed the mice do not develop preeclampsia.
